New stroke treatment targets Medium-Sized clots

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 y; 2. Diagnosed as acute ischemic stroke; 3. Isolated medium distal vessel occlusion (i.e. an occlusion of the M2, the M3/M4 segment of the MCA, the A1/ A2/A3 segment of the ACA or the P1/P2/P3 segment of the PCA) confirmed by CT or MR Angiography; 4. Time from onset (or last-seen-well) to randomization \< 24h; 5. Has not received intravenous thrombolysis and is considered unsuitable for it based on the treating clinician's assessment. 6. NIHSS ≥ 5, or NIHSS ≤ 4 with disabling deficit (e.g. severe aphasia, hemianopia, hemiplegia/loss of function in one side) or fluctuating symptoms at the time of randomization; 7. For patients within 6 h of onset: No visually apparent hypodensity is observed on non-contrast CT compared with the contralateral white matter, or no hyperintensity is seen on fluid-attenuated inversion recovery (FLAIR) imaging; For patients presenting 6-24 h after onset: A perfusion imaging-based ischemic core mismatch ratio \>1.2 and an infarct core volume \<50 mL are required; 8. Pre-stroke mRS ≤ 1； 9. Patient/Legally Authorized Representative has signed the Informed Consent form. Exclusion Criteria: 1. Any evidence of intracranial hemorrhage on qualifying imaging; 2. Concurrent multiple (≥2) intracranial arterial occlusions; 3. Suspected cerebral vasculitis, septic embolism, or infective endocarditis as the cause of vessel occlusion; 4. Suspected arterial dissection; 5. Clinical assessment of conditions unsuitable for interventional therapy (e.g., severe contrast agent allergy or absolute contraindications to iodine contrast agent; severe renal insufficiency, glomerular filtration rate \< 30ml/min or serum creatinine \> 220μmol/L (2.5 mg/dl)); 6. Unsuitable for arterial thrombolytic therapy (e.g., known history of hereditary or acquired hemorrhagic disease and/or platelet count \<50×109/L; abnormal coagulation function (INR\>1.7); oral anticoagulants were taken within 24 - 48 hours before onset within APTT \> 3 times normal; recent medical history or clinical manifestations of brain tumors other than meningiomas); 7. Any terminal disease with life expectancy \<1 year; 8. Pregnancy or lactation; 9. Concurrent participation in another investigational drug or device study that could interfere with the present trial; 10. Other circumstances that participation is not deemed appropriate.